M&A Deal Summary

SK Capital Partners Acquires Noramco

On July 20, 2016, private equity firm SK Capital Partners acquired life science company Noramco from Johnson & Johnson

Acquisition Highlights
  • This is SK Capital Partners’ 2nd transaction in the Life Science sector.
  • This is SK Capital Partners’ 8th transaction in the United States.
  • This is SK Capital Partners’ 1st transaction in Delaware.

M&A Deal Summary
Date 2016-07-20
Target Noramco
Sector Life Science
Buyer(s) SK Capital Partners
Sellers(s) Johnson & Johnson
Deal Type Divestiture

Target

Noramco

Wilmington, Delaware, United States
Noramco is a provider in the production of controlled substances for the pharmaceutical industry, for medicines used to treat Attention Deficit Hyperactivity Disorder, pain, addiction, and for abuse-deterrent formulations. Noramco was founded in 1979 and is based in Wilmington, Delaware.

Search 201,430 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.

DEAL STATS #
Overall 13 of 41
Sector (Life Science) 2 of 5
Type (Divestiture) 7 of 16
State (Delaware) 1 of 1
Country (United States) 8 of 27
Year (2016) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-21 Seqens

Ecully, France

Seqens is a global diversified chemicals Group that produces and distributes essential chemicals that are used in everyday products. Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies. Seqens was founded in 2003 and is based in Ecully, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-02 Calabrian

Port Neches, Texas, United States

Calabrian Corp. is a provider of sulfur dioxide and related derivatives used in wastewater treatment and other applications. The Company manufactures sulfur dioxide and downstream derivatives such as sodium sulfite, sodium bisulfite, sodium metabisulfite and sodium thiosulfate in its integrated manufacturing facility in Port Neches, TX. Its products are used in a broad range of industrial and municipal wastewater treatment applications to achieve compliance with federal and local water regulations, as well as other specialty applications in mining, personal care, pulp and paper processing, food preservation, oilfield production and disinfection.

Sell -

Seller(S) 1

SELLER

Johnson & Johnson

New Brunswick, New Jersey, United States
Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 85.2B USD (2023)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.

DEAL STATS #
Overall 12 of 18
Sector (Life Science) 2 of 2
Type (Divestiture) 11 of 16
State (Delaware) 1 of 1
Country (United States) 10 of 16
Year (2016) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-02 Vogue International

Phenix City, Alabama, United States

Vogue is a producer of hair care products. Vogue’s branded products include the OGX® collection of shampoos, conditioners and styling/treatment and body and bath items, Proganix® salon inspired hair care, and the recently-launched Maui Moisture wholesome beauty line. Vogue’s products are distributed to large retailers throughout the U.S. and in 38 countries.

Buy $3.3B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-25 Johnson & Johnson - REMBRANDT

New Brunswick, New Jersey, United States

Johnson & Johnson - REMBRANDT is a developer of whitening toothpaste and later expanded its product offerings within the dental whitening category. The brand is synonymous with quality whitening products and provides Ranir an additional platform for the growing teeth whitening segment.

Sell -
Mergr

Product

Company

Legal